Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
484.24
+3.91 (0.81%)
At close: Feb 21, 2025, 4:00 PM
489.00
+4.76 (0.98%)
After-hours: Feb 21, 2025, 4:47 PM EST
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 23 analysts with 12-month price forecasts for Vertex Pharmaceuticals stock have an average target of 505.61, with a low estimate of 408 and a high estimate of 586. The average target predicts an increase of 4.41% from the current stock price of 484.24.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock from 25 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 10 | 11 | 12 | 10 | 10 |
| Buy | 9 | 8 | 8 | 8 | 7 | 6 |
| Hold | 7 | 9 | 9 | 9 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 26 | 28 | 29 | 30 | 27 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $407 → $408 | Hold | Maintains | $407 → $408 | -15.74% | Feb 20, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Sell → Hold Upgrades $408 → $424 | Strong Sell → Hold | Upgrades | $408 → $424 | -12.44% | Feb 12, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $460 → $520 | Strong Buy | Maintains | $460 → $520 | +7.38% | Feb 11, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $402 → $407 | Hold | Maintains | $402 → $407 | -15.95% | Feb 11, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $433 → $450 | Hold | Maintains | $433 → $450 | -7.07% | Feb 11, 2025 |
Financial Forecast
Revenue This Year
12.19B
from 11.02B
Increased by 10.63%
Revenue Next Year
13.28B
from 12.19B
Increased by 8.91%
EPS This Year
18.38
from -2.08
EPS Next Year
20.44
from 18.38
Increased by 11.21%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.1B | 14.8B | 17.1B | ||
| Avg | 12.2B | 13.3B | 14.5B | ||
| Low | 11.3B | 11.6B | 11.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.7% | 21.7% | 28.7% | ||
| Avg | 10.6% | 8.9% | 9.1% | ||
| Low | 2.7% | -4.8% | -12.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20.56 | 28.71 | 36.40 | ||
| Avg | 18.38 | 20.44 | 23.05 | ||
| Low | 15.62 | 16.23 | 18.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 56.2% | 78.1% | ||
| Avg | - | 11.2% | 12.8% | ||
| Low | - | -11.7% | -8.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.